Daewoong Pharm. Co., Ltd. (CEO/Lee Jong-wook) announced on 24 July that It was ready to produce the raw materials of 'Tamiflu', medicine for the new flu which is actually in short supply.

Daewoong possesses all manufacturing techniques for compounding the raw materials of Tamiflu to produce the end product.

Tamiflu is one and only medicine for the new flu approved by the WHO. Roche is exclusively supplying it to all countries, having its substance patent till 2016.

And with the spread of the new flu, Tamiflu in stock is running short.

In an ordinary situation, it takes about one year just for the permission of the generic Tamiflu production.

But with the invocation of the compulsive enforcement right, it can be possible to make the end product within a couple of months.

Daewoong has already had the experience of manufacturing the end product of Tamiflu when the bird flu had prevailed between 2005 and 2006. [헬스코리아뉴스]

▶ 대웅제약 "타미플루 원료 생산 준비 완료"

Healthkoreanews 다른기사 보기